Bank Of America Corp Aprea Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 10, 2023	BUY	$0.32 - $15.2 $37 - $1,793	118 New	118 $0
Q2 2022 Aug 12, 2022	SELL	$0.62 - $1.94 $2,470 - $7,730	-3,985 Reduced 95.27%	198 $0
Q1 2022 May 16, 2022	BUY	$1.59 - $3.16 $6,428 - $12,775	4,043 Added 2887.86%	4,183 $8,000
Q4 2021 Feb 08, 2022	SELL	$2.87 - $5.58 $29,176 - $56,726	-10,166 Reduced 98.64%	140 $0
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.63 $16,086 - $26,404	4,690 Added 83.51%	10,306 $53,000
Q2 2021 Sep 13, 2021	BUY	$4.05 - $5.5 $22,744 - $30,888	5,616 New	5,616 $27,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,741
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.